23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Företagslösning
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Välkommen till vår företagslösning

    Här kan du administrera användarna i din företagslösning.

  • Välkommen till din prenumeration för Life Science Sweden.

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Sweden.

  • Click here to go to sign-up
Logga in eller skapa en prenumeration för att spara artiklar
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Prova Life Science Sweden nu
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
Annons
Annons
News in English

First injectable cancer medicine for home use receives green light

Johnson & Johnson has announced that its blockbuster cancer medicine Darzalex (daratumumab) is set to become the first injectable cancer treatment in Europe suitable for self-administration.
Annons

The European Medicines Agency’s scientific committee for human medicines (CHMP) has issued a positive opinion on a Type II variation to the product information for daratumumab in its subcutaneous formulation.

According to Johnson & Johnson Innovative Medicine, this makes it the first injectable oncology medicine in Europe to be recommended for self-administration.

Annons Annons
BREAKING
{{ article.headline }}
0.156|